Abstract
Here we describe the rational design, computer-aided virtual ligand docking and synthesis of 19 nonpeptidic compounds designed to inhibit histone deacetylases and kill melanoma cells. Compounds were derived from cysteine, fused at the S-terminus to 4-butanoyl hydroxamate, and at the N-terminus to 4-(dimethylamino)benzoic acid. The latter was extended by coupling to amines to form a small library of prospective anti-cancer compounds. Four compounds were cytotoxic at sub-micromolar concentrations against cells of a particularly aggressive human melanoma (MM96L), and nine compounds showed selectivities of ≥ 5:1 for killing human melanoma instead of normal human fibroblast cells. The most active compounds were shown to cause hyperacetylation of histones due to inhibition of histone deacetylases. Further refinement of these compounds may produce an anti-tumor drug suitable for treating melanoma.
Keywords: drug design, inhibitor, anti-cancer, cancer, melanoma, Histone deacetylase
Medicinal Chemistry
Title: New Cysteine Derivatives with Antiproliferative Activity on Melanoma Cells
Volume: 2 Issue: 2
Author(s): D. P. Fairlie, P. G. Parsons, A. J. Lucke and G. M. Boyle
Affiliation:
Keywords: drug design, inhibitor, anti-cancer, cancer, melanoma, Histone deacetylase
Abstract: Here we describe the rational design, computer-aided virtual ligand docking and synthesis of 19 nonpeptidic compounds designed to inhibit histone deacetylases and kill melanoma cells. Compounds were derived from cysteine, fused at the S-terminus to 4-butanoyl hydroxamate, and at the N-terminus to 4-(dimethylamino)benzoic acid. The latter was extended by coupling to amines to form a small library of prospective anti-cancer compounds. Four compounds were cytotoxic at sub-micromolar concentrations against cells of a particularly aggressive human melanoma (MM96L), and nine compounds showed selectivities of ≥ 5:1 for killing human melanoma instead of normal human fibroblast cells. The most active compounds were shown to cause hyperacetylation of histones due to inhibition of histone deacetylases. Further refinement of these compounds may produce an anti-tumor drug suitable for treating melanoma.
Export Options
About this article
Cite this article as:
Fairlie P. D., Parsons G. P., Lucke J. A. and Boyle M. G., New Cysteine Derivatives with Antiproliferative Activity on Melanoma Cells, Medicinal Chemistry 2006; 2 (2) . https://dx.doi.org/10.2174/157340606776056124
DOI https://dx.doi.org/10.2174/157340606776056124 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Excessive Indoor Tanning as a Behavioral Addiction: A Literature Review
Current Pharmaceutical Design Immunotherapy of Cancer Based on DC-Tumor Fusion Vaccine
Current Immunology Reviews (Discontinued) Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Antipsoriatic Drug Development: Challenges and New Emerging Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Apis mellifera Proteomics: Where Will the Future Bee?
Current Proteomics Liposomal Targeting of Angiogenic Vasculature
Current Drug Delivery Reactive Oxygen Production Induced by the Gut Microbiota: Pharmacotherapeutic Implications
Current Medicinal Chemistry The Role Oxidative Stress in the Pathogenesis of Eye Diseases: Currnt Status and a Dual Role of Physical Activity
Mini-Reviews in Medicinal Chemistry Lysophospholipids: Synthesis and Biological Aspects
Current Organic Chemistry Proteasome Inhibitors in Cancer Therapy
Current Drug Targets HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Inflammatory Network
Inflammation & Allergy - Drug Targets (Discontinued) TRICOM Vector Based Cancer Vaccines
Current Pharmaceutical Design Sequence and Time Dependence of Transfection Efficiency of Electrically- Assisted Gene Delivery to Tumors in Mice
Current Drug Delivery Gliomagenesis and the Use of Neural Stem Cells in Brain Tumor Treatment
Anti-Cancer Agents in Medicinal Chemistry Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation
Current Pharmaceutical Design Induction of HT-29 Colon Cancer Cells Apoptosis by Pyrogallol with Growth Inhibiting Efficacy Against Drug-Resistant Helicobacter pylori
Anti-Cancer Agents in Medicinal Chemistry Cellular Uptake of Neutral Phosphorodiamidate Morpholino Oligomers
Current Pharmaceutical Biotechnology Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Positron Emission Tomography Imaging of Tumor Hypoxia
Current Medical Imaging Novel Approaches to Modulate Apoptosis Resistance: Basic and Clinical Implications in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Current Drug Delivery